Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


U.K. commission on nano

This article was originally published in The Tan Sheet

Executive Summary

There is no evidence of environmental or health risks from nanomaterials, and thus no need to ban nanotechnology, the U.K.'s Royal Commission on Environmental Pollution says in a Nov. 12 report. The advisory panel calls for more testing on nanoparticles' functionality, a research program and government flexibility to address nanotechnology and other nascent fields. RCEP Chairman John Lawton calls for extending the coverage of the European Union's REACH chemical regulation to nanomaterials, as "the rate of innovation in this sector far outstrips our capacity to respond to the risks." The European Commission has advised EU members not to research nanoparticles in food and personal care items until more risk assessments are completed (1"The Tan Sheet" Oct. 20, 2008, In Brief)

You may also be interested in...

Euro nano opinion

The European Food Safety Authority's Scientific Committee opens for comment Oct. 17 a draft scientific opinion on the potential risks of nanotechnologies for food. The opinion, requested by the European Commission to help develop appropriate legislation, says that established risk assessment approaches apply to nanoscience, though "it is generally not possible to extrapolate the potential toxicity of [engineered nanomaterials] from information on dissolved or macroscale chemicals." EFSA will accept comments until Dec. 1 at The EC advised European Union members to avoid clinical research on nanoparticles in food and personal care products until it learns more about their biological and environmental effects (2"The Tan Sheet" Feb. 25, 2008, p. 12)

EMA's Decision On Ranitidine Remaining Available Could Come At End Of April

Following the US request for ranitidine drugs to be withdrawn from the market, the European Medicines Agency says it would decide the fate of the products in the EU after wrapping up its own inquiry.

Perrigo Has Approval For Copy Of OTC Voltaren Arthritis Relief Before GSK Launches The Brand

Perrigo will launch generics of GSK's OTC Voltaren Arthritis Pain drug later in 2020 following FDA approval of its ANDA. GSK, which received FDA's OTC switch approval in February, still hasn't launched the product or indicated when it will.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts